BDNF polymorphism and association with bipolar disorder
OwnerPamela Sklar, Eric S. Lander +2inventors
InventorsPamela Sklar, Eric S. Lander, J. Raymond DePaulo JR., Melvin G. McInnis
Life of this patent
Estimating the term…
Abstract
Methods for diagnosing and treating neuropsychiatric disorders, especially bipolar disorder, and to methods for identifying compounds for use in the diagnosis and treatment of neuropsychiatric disorders are disclosed. Also disclosed are novel compounds and pharmaceutical compositions for use in the diagnosis and treatment of neuropsychiatric disorders such as bipolar disorder.
Claims23
A kit for determining the genotype of an individual at a nucleotide corresponding to position 31 of a BDNF gene in a polynucleotide sequence of interest comprising;
- a) one or more nucleic acid probes, wherein at least one of said probes hybridizes to the polynucleotide sequence, wherein the polynucleotide sequence comprises the BDNF gene, its complement, or portion thereof, and wherein the polynucleotide sequence includes a nucleotide corresponding to position 31 of SEQ ID NO:
- 1;
- and
- b) control nucleic acid samples representing the genotype of at least one of the group consisting of:
- an individual homozygous for a “A” at nucleotide position 31 of the BDNF gene, an individual homozygous for a “T” at nucleotide position 31 of the BDNF gene, and an individual heterozygous for said position, wherein position 31 corresponds to position 31 of SEQ ID NO:
- 1.
A nucleic acid molecule comprising a nucleic acid sequence which is at least 10 nucleotides in length, wherein said nucleic acid molecule includes a nucleotide corresponding to position 31 of SEQ ID NO:
- 1 or its complement, wherein said nucleotide at position 31 of SEQ ID NO:
- 1 is an “A”.
A method for predicting the likelihood that an individual will be diagnosed with a bipolar disorder, comprising the steps of,
- a) obtaining a DNA sample from an individual to be assessed;
- and
- b) determining the nucleotide present at nucleotide position 31 of brain-derived neurotrophic factor gene, as numbered in SEQ ID NO:
- 1,
- wherein the presence of a “T” at position 31 indicates that the individual has a reduced likelihood of being diagnosed with a bipolar disorder as compared with an individual having an “A” at that position.
A method for predicting the likelihood that an individual will be diagnosed with a bipolar disorder, comprising the steps of;
- a) obtaining a DNA sample from an individual to be assessed;
- and
- b) determining the nucleotide present at nucleotide position 31 of brain-derived neurotrophic factor gene, as numbered in SEQ ID NO:
- 1,
- wherein the presence of a “A” at position 31 indicates that the individual has an increased likelihood of being diagnosed with a bipolar disorder as compared with an individual having an “T” at that position.
An oligonucleotide microarray having immobilized thereon a plurality of probes, wherein at least one of said probes is specific for the variant form of the single nucleotide polymorphism at position 31 of SEQ ID NO:
- 1.
An oligonucleotide microarray having immobilized thereon a plurality of probes, wherein at least one of said probes is specific for the reference form of the single nucleotide polymorphism at position 31 of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.